ENDOPHILIN A3 IMMUNOHISTOCHEMICAL HETEROGENEITY IN PANCREATIC DUCTAL ADENOCARCINOMA

Authors

  • Andreea RUSU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Ludmila LOZNEANU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Simona-Eliza GIUSCA “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Irina-Draga CARUNTU “Grigore T. Popa” University of Medicine and Pharmacy Iasi

Abstract

Background and aim: Pancreatic ductal adenocarcinoma (PDAC) represents a malignant proliferation with minimally improved survival in last decades that presents systematic changes in classification framework based on new molecular and morphological data. Endophilin A3 (EndoA3), a protein involved in non-conventional endocytosis that was recently integrated in modulation of tumor cell adhesion molecule CD166/ALCAM, has not been evaluated in PDAC. Materials and methods: EndoA3 immunoreaction were qualitatively and semi-quantitatively analyzed in 87 cases of PDAC. Statically association between classic PDAC prognostic factors and Endophilin A3 immunohistochemical profile were evaluated. Results: Data analysis revealed that EndoA3 immunoprofile is associated with tumor degree of differentiation (p = 0.01). For the others microscopic prognostic factors there were no significant statistical correlations. Although not statistically significant, patients with high EndoA3 score presented the lowest survival. Conclusions: Endophilin A3 expressed in PDAC presents a cytoplasmic, diffuse or granular, tumor staining, but also a stromal staining. High EndoA3 immunoexpression appears to be associated with a negative prognosis in PDAC.

Author Biographies

  • Andreea RUSU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Medicine
    Department of Morpho-Functional Sciences (I)

  • Ludmila LOZNEANU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Medicine
    Department of Morpho-Functional Sciences (I)

  • Simona-Eliza GIUSCA, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Medicine
    Department of Morpho-Functional Sciences (I)

  • Irina-Draga CARUNTU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

    Faculty of Medicine
    Department of Morpho-Functional Sciences (I)

References

1. Gill AJ, Klimstra DS, Lam AK, Washington MK. Tumors of the pancreas. In: D Lokuhetty, V White V, R Watanabe, I Cree editors. WHO Classification of Tumors of the Digestive System. Lyon, Frace: IARC Press, 2019, 295-332.
2. Dell'Aquila E, Fulgenzi CAM, Minelli A, et al. Prognostic and predictive factors in pancreatic cancer. Oncotarget 2020; 11: 924-941.
3. Kjaerulff O, Brodin L, Jung A. The structure and function of endophilin proteins. Cell Biochem Biophys 2011; 60: 137-154.
4. Poudel KR, Roh-Johnson M, Su A, et al. Competition between TIAM1 and membranes balances endophilin A3 activity in cancer metastasis. Dev Cell 2018; 45: 738-752.e6.
5. Lin Z, Liu Z, Tan X, Li C. SH3GL3 functions as a potent tumor suppressor in lung cancer in a SH3 domain dependent manner. Biochem Biophys Res Commun 2021; 534: 787-794.
6. Khan I, Steeg PS. Endocytosis: a pivotal pathway for regulating metastasis. Br J Cancer 2021; 124: 66-75.
7. Shafaq-Zadah M, Dransart E, Johannes L. Clathrin-independent endocytosis, retrograde trafficking, and cell polarity. Curr Opin Cell Biol 2020; 65: 112-121.
8. Renard HF, Tyckaert, F, Lo Giudice C, et al. Endophilin-A3 and galectin-8 control the clathrin-independent endocytosis of CD166. Nat Commun 2020; 11: 1457.
9. Sun H, Bhandari K, Burrola S, Wu J, Ding WQ. Pancreatic ductal cell-derived extracellular vesicles are effective drug carriers to enhance paclitaxel’s efficacy in pancreatic cancer cells through clathrin-mediated endocytosis. Int J Mol Sci 2022; 23: 4773.
10. JD Brierley, MK Gospodarowicz, C Wittekind, editors. TNM Classification of malignant tumours, Oxford, New Jersey: John Wiley & Sons, Inc. 2017, 102-105.
11. Schlitter AM, Segler A, Steiger K et al. Molecular, morphological and survival analysis of 177 resected pancreatic ductal adenocarcinomas (PDACs): identification of prognostic subtypes. Sci Rep 2017; 7: 41064.
12. Kalimuthu SN, Wilson GW, Grant RC, et al. Morphological classification of pancreatic ductal adeno-carcinoma that predicts molecular subtypes and correlates with clinical outcome. Gut 2020, 69: 317-328
13. Coppola D, Khalil F, Eschrich SA, Boulware D, Yeatman T, Wang HG. Down-regulation of Bax-interacting factor-1 in colorectal adenocarcinoma. Cancer 2008; 113: 2665-2670.
14. Renard HF, Boucrot E. Unconventional endocytic mechanisms. Curr Opin Cell Biol 2021; 71: 120-129.
15. Delic S, Lottmann N, Jetschke K, Reifenberger G, Riemenschneider MJ. Identification and functional validation of CDH11, PCSK6 and SH3GL3 as novel glioma invasion-associated candidate genes. Neuropathol Appl Neurobiol 2012; 38: 201-212.
16. Aramaki Y, Ogawa K, Toh Yet al. Direct interaction between metastasis-associated protein 1 and endophilin 3. FEBS Lett 2005; 579: 3731-3736.
17. Tachezy M, Zander H, Marx AH, et al. ALCAM (CD166) expression and serum levels in pancreatic cancer. PLoS One 2012; 7: e39018.
18. Fujiwara, K, Ohuchida K, Sada M, et al. CD166/ALCAM expression is characteristic of tumorigenicity and invasive and migratory activities of pancreatic cancer cells. PLoS One 2014, 9: e107247.
19. Yang Y, Sanders AJ, Ruge F, et al. Activated leukocyte cell adhesion molecule (ALCAM)/CD166 in pancreatic cancer, a pivotal link to clinical outcome and vascular embolism. Am J Cancer Res 2021; 11: 5917-5932.

Additional Files

Published

2023-12-21

Issue

Vol. 127 No. 4 (2023): The Medical-Surgical Journal

Section

BASIC SCIENCES

License

COPYRIGHT 
Once an article is accepted for publication, MSJ requests a transfer of copyrights for published articles.

COPYRIGHT TRANSFER FORM FOR 

REVISTA MEDICO-CHIRURGICALĂ A SOCIETĂȚII DE MEDICI ȘI NATURALIȘTI DIN IAȘI /

THE MEDICAL-SURGICAL JOURNAL OF THE SOCIETY OF PHYSICIANS AND NATURALISTS FROM IASI

We, the undersigned authors of the manuscript entitled

_____________________________________________________________________________________

_____________________________________________________________________________________

warrant that this manuscript, which is submitted for publication in the REVISTA MEDICO-CHIRURGICALĂ, has not been published and it is not under consideration for publication in another journal.

  1. we give the consent for publication in the REVISTA MEDICO-CHIRURGICALĂ, in printed and electronic format and we transfer unconditioned and complete the copyright of this manuscript to the REVISTA MEDICO-CHIRURGICALĂ, in the event of its acceptance.
  2. the manuscript does not break the intellectual property rights of any other person.
  3. we have read the submitted version of the manuscript and we are fully responsible for the content.

Names and signatures of authors / copyright owners (the following sequence is the authorship of the article):

  1. ______________________________/_________________________
  2. ______________________________/_________________________
  3. ______________________________/_________________________

N.B.  All the authors must sign this form